Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 211-199-0 | CAS number: 633-96-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 2 011
- Report date:
- 2011
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- not specified
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Sodium 4-[(2-hydroxy-1-naphthyl)azo]benzenesulphonate
- EC Number:
- 211-199-0
- EC Name:
- Sodium 4-[(2-hydroxy-1-naphthyl)azo]benzenesulphonate
- Cas Number:
- 633-96-5
- Molecular formula:
- C16H12N2O4S.Na
- IUPAC Name:
- sodium;4-[(2E)-2-(2-oxonaphthalen-1-ylidene)hydrazinyl]benzenesulfonate
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Strain: Wistar
HanIbm: WIST (SPF)
Body weight males: mean 141 g (123-163 g)
Body weight females: mean 123 g (98-143 g)
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: water + 1% CMC
- Duration of treatment / exposure:
- 7 days per week for at least 13 weeks
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
0
Basis:
nominal in diet
- Remarks:
- Doses / Concentrations:
2.5 mg/kg bw
Basis:
nominal in diet
- Remarks:
- Doses / Concentrations:
5 mg/kg bw
Basis:
nominal in diet
- Remarks:
- Doses / Concentrations:
10 mg/kg bw
Basis:
nominal in diet
- No. of animals per sex per dose:
- 10 male and 10 females for each concentration
- Control animals:
- yes, concurrent no treatment
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- No mortality and no clinical signs were observed.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- No mortality and no clinical signs were observed.
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- see "details on results"
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- see "details on results"
- Details on results:
- Changes in haematology were evident in males treated with 5 and 10 mg/kg bw/day.
Changes in haematological parameters like increased methemoglobin levels in males up to 2.5 mg/kg bw/day and females up to 5 mg/kg bw/day, decreased haemoglobin levels in males (5 and 10 mg/kg bw/day) increased reticulocyte counts (relative and absolute) in all test article treated males and a general shift towards high fluorescent reticulocytes in high dosed males.
The changes noted in methemoglobin levels and reticulocte counts in males treated with 2.5 mg/kg bw/day were within the upper levels of the historical control data.
When compared with similarly high values at 5 mg/kg bw/day, there was no correlation to pathomorphological (extramedullary hemopoiesis in the spleen) or other haematological parameters at 2.5 mg/kg bw/day.
In males treated with 10 mg/kg bw/day, increased organ/body weight ratio in the spleen was noted, which correlated to microscopic findings (extramedullary hemopoiesis in the spleen in all animals treated with 5-10 mg/kg bw/day.
No test article related macroscopic findings were observed during necropsy.
With regard to the results obtained this, especially to changes in haematological parameters of males, the No Observed Adverse Effect Level (NOAEL) of Acid Orange 7 was considered to be in the general range around 2.5 mg/kg bw/day.
This dose led to borderline effects on met-hemoglobin and reticulocytes counts without concurrent effects on the spleen.
The NOAEL for females was set to 2.5 mg/kg bw/ day by the study authors.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 2.5 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical signs
- mortality
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- The value of NOAEL for repeated dose toxicity was established at 2.5 mg/kg bw/day both for males and females.
Based on the test result, Acid Orange 7 needs to be considered as toxic for oral repeated dose with classiifcation under CLP as Cat. 1 STOT RE, H372: Causes damage to organs through prolonged or repeated exposure - Executive summary:
The value of NOAEL for repeated dose toxicity was established at 2.5 mg/kg bw/day both for males and females.
It should be noted that at this dose, some slight early haematological effects (increased met-haemoglobin levels in males and increased reticulocytes count) are already observed.
Even if there are in the upper limits of the historical control values, this finding could be test article related. Therefore, the dose of 2.5 mg/kg bw /day is considered as the LOAEL. Based on the test result, Acid Orange 7 needs to be considered as toxic for oral repeated dose with classification under CLP as Cat. 1 STOT RE, H372: Causes damage to organs through prolonged or repeated exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
